Company Profile
Insmed Stock Price, News & Analysis
- Ticker:
- INSM
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
104.73 USD (-2.05%)
Close
Last updated: July 27, 2026
22.5B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, INSM closed down 2.05% at $104.73. No new same-company headline was identified in the current news window.
Company overview
Business overview
Insmed is a rare-respiratory company focused on severe lung disease, with ARIKAYCE and a broader pipeline in bronchiectasis and related conditions.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Insmed sits in specialty biopharma.
Business Model Characteristics
The business combines commercial rare-disease revenue with pipeline expansion into chronic respiratory indications.
Position Within the Biotechnology Landscape
Insmed occupies a strong niche where respiratory differentiation and launch execution can move the stock materially.
Future catalysts
Insmed's catalysts are brensocatib in bronchiectasis, ARIKAYCE execution, and any step that deepens the pulmonary franchise. The stock will care about whether the late-stage lung story keeps broadening.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
- 02
- 03
Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
ABEO · Source: Abeona Therapeutics
- 04
- 05
Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026
LUNG · Source: Pulmonx
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Insmed (INSM)?
Insmed (INSM) most recently closed at 104.73 USD, a -2.05% move versus the previous session.
What is the market cap of Insmed (INSM)?
Insmed currently has a market capitalization of 22.5B USD on BioPharmSignal.
What does Insmed do?
Insmed is a rare-respiratory company focused on severe lung disease, with ARIKAYCE and a broader pipeline in bronchiectasis and related conditions.
On which exchange is INSM stock listed?
Insmed (INSM) is associated with NASDAQ, United States, Biopharma.
What is Insmed?
Insmed's catalysts are brensocatib in bronchiectasis, ARIKAYCE execution, and any step that deepens the pulmonary franchise.
Which conditions is Insmed targeting with Insmed?
Insmed is associated with respiratory disease based on its company overview and current catalyst commentary.
How does Insmed describe recent progress with Insmed?
Insmed's catalysts are brensocatib in bronchiectasis, ARIKAYCE execution, and any step that deepens the pulmonary franchise.
What future catalysts are investors watching for Insmed?
Insmed's catalysts are brensocatib in bronchiectasis, ARIKAYCE execution, and any step that deepens the pulmonary franchise. The stock will care about whether the late-stage lung story keeps broadening.